4Bio hopes to mix and match next-gen therapies with $150M fund
4Bio Capital is aiming for early stage, highly innovative companies developing ‘advanced therapies’
4Bio Capital is aiming to invest solely in new modalities and treatment paradigms with its new venture fund, including in start-ups that combine more than one novel approach.
The firm has raised $50 million in the first close of 4Bio Ventures II, for which it has set a $150 million target. It will